AzTrials
AzTrials

Liver FailureELIPTO-2NCT04732689

Intraoperative Hemodynamic Management and Postoperative Outcomes in Liver Transplantation

An observational study of Liver Failure and Liver Diseases, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The overarching objective of the research program entitled ELIPTO (Enhancing Liver Insufficiency and Postoperative Transplantation Outcomes) (www.elipto.ca) is to improve the perioperative care of liver transplant recipients. Read more about this study

Who is it for?
Any age
Conditions the study is for
Liver Failure, Liver Diseases, Surgery
How many people
852 participants
Where
1 siteCanada
Study dates
1 Jan 2021to 30 Nov 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The investigators will include all recipients of a liver transplant across six Canadian centres, as well as in one French Centre.

Who may be able to join

  • All consecutive adult liver transplant recipients in each center during a one-year period or more (anywhere in between June 1, 2021 and November 30, 2022).

Who cannot join

  • Same patients who undergo a retransplantation during the same period of observation.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Centre Hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, H2X 3E4

Other trials in Canada

About this study

Official title: Intraoperative Hemodynamic Management and Postoperative Outcomes in Liver Transplantation: a Multicenter Prospective Cohort Study

The overarching objective of the research program entitled ELIPTO (Enhancing Liver Insufficiency and Postoperative Transplantation Outcomes) (www.elipto.ca) is to improve the perioperative care of liver transplant recipients. One of this program's purposes is to better define the effects of intraoperative hemodynamic management on postoperative outcomes in adult liver transplant recipients. In this study, the incidence of postoperative complications within this population will be defined in Canada and France and the association between intraoperative hemodynamics and postoperative outcomes will be measured.

Liver transplantation improves the survival of patients with end-stage liver disease (ESLD). It is the second most transplanted organ with a continuously increasing annual number of transplantations, an observation partly explained by an endemic ESLD etiology in the United States, the obesity-related non-alcoholic steatohepatitis (NASH) cirrhosis. In recent decades, although sicker patients are prioritized, survival has improved possibly through an overall improvement in the quality of care. However, postoperative complications have concomitantly increased. On average, liver transplant recipients suffer from more than three postoperative complications, mainly infectious, pulmonary, renal or graft-related, two thirds of them being severe. In a low-risk patients cohort, close to 60% of all patients suffered from at least one severe complication up to 6 months after surgery. Such complications increase mortality, readmissions and cost of care. Organs available for transplantation are a scarce resource; up to 10% of grafts are no longer functional after one year. Interventions that improve patients' postoperative and graft outcomes are needed and few perioperative ones are supported by high-quality evidence.

Read the detailed description

OBJECTIVES:

The main objective of this study is to describe and measure the effects of intraoperative hemodynamic management on postoperative outcomes in liver transplantation in Canada and France.

The specific objectives are:

  1. To describe the overall incidence of postoperative complications and graft outcomes in adult liver transplant recipients in Canada and France and across different recipients' characteristics.
  2. To measure the effects of fluid balance, within an overall hemodynamic instability and management strategy, on the postoperative outcomes of liver transplant recipients in Canada and France.

The central hypotheses of this study are that an intraoperative hemodynamic management based on a restrictive fluid administration may improve postoperative outcomes in this population.

EXPOSURE VARIABLES:

The exposures of interest will be the intraoperative fluid balance and the intraoperative doses and types of vasopressors used. Fluid balance will be defined as the sum of the volume of administered crystalloids, colloids and blood product transfusions minus drained ascites, intraoperative diuresis and bleeding. Doses of administered vasopressors will be converted into a time-weighted total norepinephrine equivalent dose calculated as the total equipotent units of norepinephrine administered as an infusion divided by the number of hours the infusion was given during the period between entrance in the operating room and end of surgery. Types of vasopressors used will also be collected. Since a restrictive fluid management strategy is associated with a higher use of vasopressors and vice versa, both variables may covary together. However, more difficult surgeries will be associated with higher blood loss, higher volume of administered fluid and higher doses of vasopressors. The combination of these two variables will help estimate the intraoperative hemodynamic management strategy used and delineate the effects of each component.

OTHER DESCRIPTIVE VARIABLES:

Other patients' characteristics and perioperative practices variables will be captured for descriptive purposes. Recipients' demographic characteristics (age, sex), anthropometric variables (body mass index (BMI)), the presence of any previous abdominal surgery, presence of hepatic encephalopathy, need for preoperative organ support or any preoperative hospital admission will be collected as well. Data on the perioperative use of invasive cardiac output monitoring (thermodilution catheter, transoesophageal echocardiography, etc.), as well as coagulation management (use of thromboelastometry, tranexamic acid, transfusion thresholds, etc.) will be collected. Other donor and graft variables, such as donor sex, donor's BMI, the type of vascular and biliary anastomoses, the use of extended-criteria donor graft, the use of ex vivo perfusion, ischemia time, the practice of donation after circulatory death (donor characteristics, heparin usage, etc.) and the perioperative use of liver biopsies will also be collected.

DESCRIPTIVE AND STATISTICAL ANALYSIS:

Missing data The investigators will train all sites regarding quality of data collection and will emphasize the importance of complete data collection. In case a complete case analysis would exclude more than 5% of the observations, the investigators will use multiple imputations by chained equations using 5 to 20 imputated datasets assuming MAR (missingness at random) on the covariables and the outcomes.

Descriptive analyses and complications incidences across centers The investigators will first describe the cumulative incidences of different complications or categories of complications as previously defined. Their main descriptive analysis will be to report these incidences overall as well as across denominated centers. Then, they will estimate multivariable determination models for each complication category by fitting generalized mixed effect models using a logit link adjusted for age, sex, disease severity (MELD), transplantation indication, requirement for preoperative organ support and donor characteristics with an estimated random-effect for clustering within centres. The investigators will then compute intra-class correlation (ICC) coefficients to better define the variability of complications across centres (heterogeneity). However, they will fit a Cox regression with a shared frailty factor for biliary complications. Finally, they will fit a generalized mixed effect model using a log link and quasi-Poisson distribution for the total number of complications up to 30 days per patient with an estimated random effect for clustering within centres. Their secondary exploratory analyses will be to report the cumulative incidence of each complication according to age categories (< 50, 50-60, >60), sex, nature and severity of liver disease (chronic liver disease (CLF), acute liver failure (ALF), retransplantation and MELD categories among CLD patients (< 20, 20-30, >30). They will report such incidences per subgroups with 95% confidence intervals. They will also report survival up to 6 months over and across centres by fitting a Cox regression with a frailty factor.

Association between hemodynamic management and postoperative complications The investigators' primary analysis will be the association between fluid volume and primary graft dysfunction by 7 days after transplantation using a multivariable generalized mixed-effect model using a logistic link and random intercepts, adjusted for the time-weighted dose of vasopressors and the aforementioned confounders, and estimated using residualized penalized quasi-likelihood. They will consider any patient needing a retransplantation within 7 days after the index transplantation as having a primary graft dysfunction. Statistical interaction will be explored between fluid balance and the vasopressors dose variable.

The investigators' other secondary analyses will be the association between fluid volume and other outcomes, including AKI and the total number of complications up to 30 days, using similar adjusted survival models (with frailty factors) or generalized mixed effect models (with random intercepts). Among them, the investigators will analyze the association between fluid volume and time to biliary non-anastomotic strictures using a multivariable Fine and Gray model, adjusted for the same confounders, with retransplantation and death (not caused by the biliary non-anastomotic strictures) considered as competing risks. They will address intra-cluster correlation using a frailty factor. Risk proportionality over time will be explored using the Harrel and Lee test and a visual inspection of the Schoenfeld residuals.

Subgroup analysis The investigators will conduct a subgroup analysis comparing the effect of their exposures on the primary outcome in the subgroup of patients transplanted for end-stage liver disease and those transplanted for causes other than end-stage liver disease. The investigators will thus estimate the same model but with an interaction term between the fluid volume and a dummy variable for end-stage liver disease. They will report stratified results with 95% CI and the interaction test p value.

Sensitivity analyses For the primary outcome, the main secondary outcome and the total number of complications at 30 days, the investigators will first conduct a sensitivity analysis using a generalized propensity score for fluid volume (based on probability density) that will include all confounders and the vasopressor exposure and estimate a marginal effect of fluid balance using an inverse probability of treatment weighting with stabilized weights. The investigators will evaluate the confounding effect of hypotension by removing it from the models as well as by a sensitivity analysis restricted in the subgroup of patients without significant residual hypotension. Finally, they will conduct all analyses by adding data from the French centre to explore the variation in the estimates created by adding a non-Canadian centre.

Economic analysis The investigators will conduct an economic analysis to evaluate hospital costs associated with the observed incidences of postoperative complications. They will also analyze costs associated with their fluid balance exposure effect. Costs will be those associated with the actual procedures, as determined by every hospital using its account systems, and include both fixed and variable components previously identified as major cost drivers (mechanical ventilation days, LOS, reoperation and ICU readmission).

Medical subject headings
Liver Failure, Liver Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04732689
Study groupRoleWhat they receive
Groups/CohortsThe investigators propose to conduct a prospective observational cohort which will include all consecutive adult liver transplant recipients in each center during a one-year period but will exclude same patients who undergo a retransplantation during the same period of observation.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occurence of primary graft dysfunction

    This outcome was chosen because preliminary data from the CHUM suggested that a higher fluid balance was associated with primary graft non-function (retransplantation or death). Since graft perfusion is correlated with cardiac output, intraoperative hemodynamic management may have an effect on graft perfusion and postoperative graft function. Also, this is a well-defined, quantitative definition, that is associated with overall graft and patient survival. Since graft loss of 10% at 1 year is a concern among the transplant community, finding causes and solutions to improve graft function is paramount.

    Measured: At 7 days after transplantation

Secondary outcomes (13)
  1. Occurrence of biliary complications

    Biliary complications have major impacts on patients' quality of life, graft survival and mortality. While biliary ducts are sensible to ischemic injury, the incidence of non-anastomotic strictures have been overlooked in previous perioperative studies. Biliary complications will be classified as any stricture (anastomotic or non-anastomotic) based on medical imaging results and/or surgical, endoscopic and radiological procedures.

    Measured: Up to 6 months after transplantation

  2. Occurence of biliary anastomotic strictures

    Biliary complications will be classified as any stricture (anastomotic or non-anastomotic) based on medical imaging results and/or surgical, endoscopic and radiological procedures.

    Measured: Up to 6 months after transplantation

  3. Liver transplant-related reoperations

    Patient having to undergo any liver transplant-related reoperations up to 30 days after transplantation.

    Measured: Up to 30 days after transplantation

  4. Retransplantation

    Retransplantation is defined as the patient having to undergo a new transplantation following the index transplantation.

    Measured: Up to 6 months after transplantation

  5. Occurence of acute kidney injury

    The grade of AKI was classified according to the KDIGO-AKI criteria using the highest reported creatinine or the need for new renal replacement therapy after surgery, including any mode of renal replacement therapy.

    Measured: 48 hours, 7 days and 30 days after transplantation

  6. Occurence of infectious complications

    Infectious complications by any antibiotic prescription lasting more than 72 hours

    Measured: Up to 30 days after transplantation

  7. Occurrence of pulmonary complications

    Pulmonary complications will be classified using standardized definitions for atelectasis and ARDS.

    Measured: Up to 30 days after transplantation

  8. The need for a new postoperative ICU admission

    The dates for all ICU admissions and dates of ICU discharge were recorded. If the patient was readmitted to ICU following his initial admission to ICU, the dates for admissions and discharges were recorded.

    Measured: Up to 30 days after transplantation

  9. 30-day mechanical ventilation free-days

    The total number of days the patient was on invasive mechanical support was recorded. If mechanical ventilation was weaned and started again, the days when the patients were under mechanical ventilation were indicated. Non-invasive ventilation or high-flow nasal cannula (HFNC) were not included.

    Measured: Up to 30 days after transplantation

  10. 30-day organ dysfunction free days

    The total number of days the patient was: on invasive mechanical ventilator, under vasopressor therapy for more than 2 hours up to 30 days after surgery and spent under renal replacement therapy was recorded.

    Measured: Up to 30 days after transplantation

  11. Hospital length of stay

    The number of days of hospital length of stay was calculated using the difference between the local date of discharge from the hospital and the date of hospital admission (day of surgery). If the patient died during surgery or prior to hospital discharge, the patient's date of death was recorded as the date of discharge.

    Measured: 30 days after transplantation

  12. Occurence of acute rejection episode

    An acute rejection episode defined as the grafted liver is attacked by the immune system.

    Measured: 30 days after transplantation

  13. Survival up to 6 months

    Survival was calculated from the date of participant initial transplant to the date of participant death due to any cause, within 6 months after the surgery.

    Measured: 6 months after transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Feb 2021
  2. Study start1 Jan 2021
  3. Primary completion30 Jun 2023
  4. Study completion30 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
852 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04732689
Sponsor's protocol ID
20.353
Acronym
ELIPTO-2
Status last verified
Feb 2025
First submitted
27 Jan 2021
Last updated
5 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Carrier FM, Ferreira Guerra S, Soucy-Proulx M, Joosten A, McCluskey S, Luzzi C, Ghai P, Papamihali K, Karvellas C, Larbi S, Sitbon A, Monsel A, Mendoza-Vasquez LE, Gonzalez-Valencia N, Kandelman S, Nooh A, Carr A, Amzallag E, Fortin E, Marceau E, Pilote L, Giard JM, Simoneau E, Duceppe E, Trottier H, Chasse M. Intraoperative Hemodynamic Management during Liver Transplantation and Postoperative Morbidity: A Multicenter Cohort Study. Anesthesiology. 2026 Aug 1;145(2):300-312. doi: 10.1097/ALN.0000000000006071. Epub 2026 Mar 30.

    PubMed 41911318

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Failure and Liver Diseases, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occurence of primary graft dysfunction (time frame: At 7 days after transplantation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04732689, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in